Related Experiment Videos
Correlation between immunophenotypic diversity and clinical features in B-cell lymphoblastic lymphoma
K Shibata1, Y Shimamoto, H Yamada
1Department of Internal Medicine, Saga Medical School, Japan.
Annals of Hematology
|December 1, 1995
Summary
B-cell lymphoblastic lymphoma (B-LBL) is a rare, diverse non-Hodgkin
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Lymphoblastic lymphoma (LBL) is a rare, aggressive non-Hodgkin's lymphoma (NHL).
- While typically T-cell in origin, a small subset exhibits a B-cell phenotype (B-LBL).
- B-LBL often presents differently from T-cell LBL, commonly involving the head and neck without central nervous system (CNS) or mediastinal involvement.
Observation:
- B-LBL is immunologically diverse, with three distinct subgroups identified.
- The predominant subgroup is CD10-positive pre-B-cell type, often presenting with head and neck masses.
- Other subgroups include CD10-negative mature B-cell type (mediastinal involvement) and CD5-positive B-cell type (blastic mantle cell lymphoma variant).
Findings:
- The CD5-positive B-cell type exhibits a less aggressive clinical course, affecting older patients with more frequent nodal than extranodal involvement.
- Immunophenotype is a key determinant of B-LBL's biological behavior and clinical presentation.
- Distinct immunological profiles correlate with specific sites of disease involvement and patient demographics.
Implications:
- Understanding B-LBL immunophenotypes is crucial for accurate diagnosis and prognostication.
- Tailoring treatment strategies based on specific B-LBL subtypes may improve patient outcomes.
- Further research into the biology of B-LBL subtypes can elucidate targeted therapeutic approaches.